Beyond Air Subsidiary Reports Compelling Early Efficacy, Favorable Safety in Phase 1 Cancer Trial
summarizeSummary
Beyond Air's subsidiary, Beyond Cancer, Ltd., announced positive interim data from its Phase 1 UNO trial for solid tumors, demonstrating early clinical activity and a favorable safety profile. The trial, involving ten heavily pretreated, end-stage cancer patients, showed that seven patients remain alive 19 to 37 months post-treatment, with two triple-negative breast cancer patients achieving no evidence of disease. This is a highly significant development for the micro-cap biotech, particularly in light of its recent 'going concern' warning, as such compelling early efficacy and safety data are critical for attracting further investment and advancing the program. The data will be presented at the AACR Annual Meeting in April, and investors will closely monitor the company's plans for subsequent clinical trial stages.
في وقت هذا الإعلان، كان XAIR يتداول عند ٠٫٩٥ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٨٫٥ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٠٫٦٧ US$ و٦٫٤٤ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٩ من 10. المصدر: GlobeNewswire.